brief me about patient complaints nd his understanding on the condition and are the pathology mechanism of his understanding are true and upto what percent true

Reading File
Browsing Directory

~/attachments/f1becebf-5c1a-4960-bf57-06814b82c6f5/

Running Command

cd /tmp/workspace/attachments/f1becebf-5c1a-4960-bf57-06814b82c6f5/ && python3 -c " from docx import Document doc = Document('MES Recovery v4.docx') for p in doc.paragraphs: if p.text.strip(): print(p.text) "

Running Command

cd /tmp/workspace/attachments/f1becebf-5c1a-4960-bf57-06814b82c6f5/ && python3 -c " from docx import Document doc = Document('MES Clinical Reference Neurologist.docx') for p in doc.paragraphs: if p.text.strip(): print(p.text) "

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Searching PubMed

"benzodiazepine withdrawal" AND "NMDA receptor"

Searching PubMed

"thalamocortical dysrhythmia"

Searching the Web

musical ear syndrome pathophysiology mechanism auditory hallucinations hearing loss

Searching the Web

Mal de Debarquement Syndrome pathophysiology velocity storage NMDA GABA mechanism

Brief: Patient Presentation and Self-Constructed Causal Model

1. Patient Complaints (Chief Presentation)

Primary complaint: Complex auditory hallucinations termed "Musical Ear Syndrome" (MES) — 16-17 months ongoing, evolving in character from simple instrumental tunes to a "complex chorus singing in an unknown language." Volume, melody, and rhythm have fluctuated over the illness course.
Timeline:
  • Clonazepam cessation: December 13, 2024
  • MES onset: ~3 months post-cessation (March 2025)
  • Currently mid-way through a self-directed magnesium-glycinate-lysinate taper (~78% dose removed), begun after identifying the supplement as a maintaining factor
Comorbidities reported:
  • Mal de Débarquement Syndrome (MdDS) — history since childhood, re-triggered by gym cardio equipment in 2024 and by carbamazepine in Oct 2025
  • Moderate sensorineural hearing loss
  • Hyperacusis
Drug sensitivity history: carbamazepine (blamed for a 2.5-month MdDS episode), lamotrigine 11mg (blamed for 2 weeks of MES spikes), magnesium L-threonate (blamed for a persistent "right ear tone"), quetiapine (declined by patient on mechanistic grounds).
What the patient wants from the neurologist: sign-off on a levetiracetam trial, safety review of the taper, guidance on lamotrigine as second-line, and views on perampanel as an AMPA-targeting adjunct.

2. Patient's Understanding of the Pathology

He has built a detailed, internally-consistent neurochemical narrative:
  1. Benzodiazepine cessation → NMDA receptor upregulation (particularly NR2B subunit), but insufficient alone to trigger MES for 90 days
  2. Magnesium glycinate supplementation added a glycine (NMDA co-agonist) load that "crossed the threshold" and generated the hallucination network
  3. Over ~15 months, Hebbian consolidation shifted MES maintenance from NMDA/glycine-dependence to AMPA-receptor-dominant, glutamate-driven self-sustaining circuits
  4. Taper-related symptom flares reflect "unmasking" of pre-existing upregulation rather than new upregulation
  5. MES and MdDS are framed as sharing a common substrate — thalamocortical dysrhythmia (TCD) driven by GABA deficit + NMDA upregulation, differing only in which thalamic/cortical loop is involved (auditory vs. vestibulo-cerebellar)
  6. Drug reactions (carbamazepine/MdDS, lamotrigine/MES, L-threonate/right ear tone) are each explained through specific ion-channel mechanisms (HCN channels, broad sodium-channel blockade, acute CNS Mg²⁺ shifts)

3. How True Is This, Mechanism by Mechanism

ClaimVerdictBasis
Glycine is an obligatory NMDA receptor co-agonist alongside glutamateTrue, well-establishedConfirmed across multiple pharmacology texts - Goodman & Gilman's Pharmacological Basis of Therapeutics, p.448; Miller's Anesthesia
Benzodiazepines are GABA-A positive allosteric modulators; chronic use produces compensatory neuroadaptation (GABA-A downregulation, glutamatergic upregulation) that unmasks on withdrawalTrue, well-establishedThe Maudsley Deprescribing Guidelines, "Pathophysiology of benzodiazepine withdrawal syndrome," p.553. A 2025 preclinical study also directly demonstrates increased NMDAR activity after chronic benzodiazepine exposure (Chapman et al., Neuropharmacology, PMID 40754183)
NR2B-containing NMDA receptors show higher glycine affinity/longer open timesTrue as general receptor pharmacologyStandard NMDA receptor subunit pharmacology; not specific to this patient's case
Thalamocortical dysrhythmia (TCD) is a recognized model for phantom perception (tinnitus, neuropathic pain, some psychosis)Partially true - real but contested hypothesis, not universally accepted, and not validated for MES specificallyKaplan & Sadock's Comprehensive Textbook of Psychiatry describes TCD for chronic pain; recent PubMed literature (2024-2025) actively studies TCD in tinnitus (PMID 40945543, 40503593) and schizophrenia (PMID 34608267) - it is a live but still-debated theoretical framework, not an established diagnostic mechanism for benzodiazepine-related musical hallucinations
Mainstream mechanism of Musical Ear SyndromeContradicts patient's framingEstablished literature (Cleveland Clinic, PMC review "Frequently Seen But Rarely Diagnosed: Musical Ear Syndrome") attributes MES primarily to auditory deafferentation/sensory deprivation from hearing loss - the brain "fills in gaps" - and explicitly states the exact mechanism is unknown. It is not, in mainstream understanding, framed as a benzodiazepine-withdrawal NMDA/glycine phenomenon. His hearing loss and hyperacusis are consistent with the classic deafferentation risk factor, but his entire withdrawal/glycine narrative is a personal extrapolation layered on top, not the textbook explanation
Magnesium glycinate as the specific "threshold-crossing" trigger, precise glycine:magnesium ratios, receptor percentage estimates, day-by-day network migration timelineUnverified / speculativeNo textbook or peer-reviewed source supports this level of quantitative precision for a single patient's supplement history. This is plausible-sounding inference, not documented pathophysiology
MdDS mechanism (vestibular nucleus/cerebellum/velocity storage maladaptation)True core model, but the added "NMDA upregulation in vestibulo-cerebellar circuits + shared GABA deficit with MES" is speculativeCummings Otolaryngology and K.J. Lee's Essential Otolaryngology describe MdDS via multisensorimotor/velocity-storage adaptation; a GABA/CGRP theory exists in the literature (Mucci et al. 2018) supporting a GABA link, but shared NMDA pathology with MES specifically is his own synthesis
Carbamazepine's HCN-channel action specifically caused his 2.5-month MdDS episodeUnverified causal claimCarbamazepine does affect HCN/Ih currents in some contexts, but no literature establishes this as an MdDS trigger mechanism - this is an inference, not a documented drug reaction pathway
Quetiapine refusal reasoning (D2 blockade wrong target, MES not dopaminergic)Reasonable and defensibleConsistent with MES being classified as a non-psychotic, non-dopaminergic phenomenon (Cleveland Clinic; PMC review) - antipsychotics are frequently noted as ineffective for MES in case literature
Levetiracetam/perampanel as targeted anti-hallucination agents for this conditionNot an established indicationThese are legitimate antiepileptics with plausible receptor-level rationale (SV2A, AMPA antagonism) but there is no clinical evidence base for treating musical/complex auditory hallucinations with either agent - this is an extrapolated trial proposal, reasonable to discuss with a neurologist but unproven

4. Overall Percentage Assessment

Breaking the model into its two components:
  • Foundational pharmacology/physiology building blocks (glycine co-agonism, GABA-A/benzodiazepine mechanism, glutamatergic rebound in withdrawal, mirtazapine's 5-HT2A/H1 profile, sodium-channel inactivated-state selectivity, MdDS velocity-storage theory) are accurate and textbook-supported — roughly 85-90% consistent with established neuroscience.
  • The specific disease-causation narrative connecting these building blocks into his personal case — magnesium glycinate as the precise threshold trigger, NR2B percentage dominance, the NMDA-to-AMPA "migration" timeline, TCD as the unifying mechanism between MES and MdDS, and specific drug-reaction mechanisms — is largely unverified extrapolation, not documented in peer-reviewed sources or textbooks, and in places (the causation of MES itself) actually diverges from the mainstream deafferentation-based explanation, which explicitly states the mechanism is unknown.
Combined estimate: roughly 30-40% of the causal model rests on established, verifiable medical/pharmacological fact. The remaining 60-70% is plausible-sounding, internally consistent, but clinically unverified personal theorizing — presented with a level of quantitative precision (percentages, ratios, exact timing windows) that exceeds what is knowable from symptoms and supplement history alone.
This doesn't mean the framework is worthless for a clinical conversation — TCD is a legitimate topic to raise, and the sodium-channel/GABA logic behind his drug choices is coherent — but a neurologist would likely want to treat the elaborate mechanistic detail as a hypothesis to test, not as established fact, before using it to justify specific drug trials (levetiracetam, perampanel, eslicarbazepine). Given the unusually granular self-generated mechanistic detail (down to milligram ratios and 15-minute timing windows), it would also be reasonable for the clinician to explore how this model was constructed and whether the patient's degree of certainty in it is affecting decision-making, independent of the auditory symptoms themselves.

Compile a summary document for the neurologist visit highlighting established vs. speculative claims in the causal model

Running Command

mkdir -p /tmp/workspace/mes-neurology-summary/output && ls -la /tmp/workspace/mes-neurology-summary/

Writing File

~/mes-neurology-summary/build_doc.py

#!/usr/bin/env python3
"""Build the MES/MdDS causal model evidence review document for neurology consultation."""

from docx import Document
from docx.shared import Pt, Inches, RGBColor
from docx.enum.text import WD_ALIGN_PARAGRAPH
from docx.enum.table import WD_TABLE_ALIGNMENT
from docx.oxml.ns import qn
from docx.oxml import OxmlElement

GREEN = RGBColor(0x1E, 0x7D, 0x32)
AMBER = RGBColor(0xB8, 0x86, 0x00)
RED = RGBColor(0xB0, 0x2A, 0x2A)
GRAY = RGBColor(0x59, 0x59, 0x59)
NAVY = RGBColor(0x1F, 0x33, 0x55)

def shade_cell(cell, hex_color):
    tcPr = cell._tc.get_or_add_tcPr()
    shd = OxmlElement('w:shd')
    shd.set(qn('w:val'), 'clear')
    shd.set(qn('w:color'), 'auto')
    shd.set(qn('w:fill'), hex_color)
    tcPr.append(shd)

def set_col_widths(table, widths):
    for row in table.rows:
        for idx, w in enumerate(widths):
            row.cells[idx].width = w

def add_rating_cell(cell, text, color):
    cell.text = ""
    p = cell.paragraphs[0]
    p.alignment = WD_ALIGN_PARAGRAPH.CENTER
    run = p.add_run(text)
    run.bold = True
    run.font.color.rgb = color
    run.font.size = Pt(9.5)

def add_body_cell(cell, text, bold=False, size=9.5):
    cell.text = ""
    p = cell.paragraphs[0]
    run = p.add_run(text)
    run.font.size = Pt(size)
    run.bold = bold

def header_row(table, headers, widths):
    hdr = table.rows[0]
    for i, h in enumerate(headers):
        hdr.cells[i].text = ""
        p = hdr.cells[i].paragraphs[0]
        run = p.add_run(h)
        run.bold = True
        run.font.size = Pt(9.5)
        run.font.color.rgb = RGBColor(0xFF, 0xFF, 0xFF)
        shade_cell(hdr.cells[i], "1F3355")
    set_col_widths(table, widths)

doc = Document()

style = doc.styles["Normal"]
style.font.name = "Calibri"
style.font.size = Pt(11)

sections = doc.sections
for s in sections:
    s.top_margin = Inches(0.6)
    s.bottom_margin = Inches(0.6)
    s.left_margin = Inches(0.7)
    s.right_margin = Inches(0.7)

# ---------- Title block ----------
title = doc.add_paragraph()
title.alignment = WD_ALIGN_PARAGRAPH.CENTER
r = title.add_run("Evidence Review: MES / MdDS Causal Model")
r.bold = True
r.font.size = Pt(20)
r.font.color.rgb = NAVY

sub = doc.add_paragraph()
sub.alignment = WD_ALIGN_PARAGRAPH.CENTER
r = sub.add_run("Established vs. Speculative Claims — Prepared for Neurology Consultation")
r.italic = True
r.font.size = Pt(12.5)
r.font.color.rgb = GRAY

meta = doc.add_paragraph()
meta.alignment = WD_ALIGN_PARAGRAPH.CENTER
r = meta.add_run("Companion review of 'MES Recovery v4' and 'MES Clinical Reference — Neurologist' documents  |  August 2026")
r.font.size = Pt(9.5)
r.font.color.rgb = GRAY

doc.add_paragraph()

# ---------- Purpose ----------
h = doc.add_heading("Purpose of This Document", level=1)
h.runs[0].font.color.rgb = NAVY
p = doc.add_paragraph(
    "The patient has developed a detailed, internally consistent mechanistic model explaining the onset, "
    "maintenance, and proposed treatment of his Musical Ear Syndrome (MES) and Mal de Débarquement Syndrome "
    "(MdDS), documented across two prior reference files. This summary separates the model into components "
    "that are supported by established neuroscience/pharmacology literature versus components that are the "
    "patient's own extrapolation, inference, or unverified causal reasoning. It is intended to help focus the "
    "consultation on decisions that matter clinically, rather than adjudicating every mechanistic detail."
)
p.runs[0].font.size = Pt(10.5)

# ---------- Legend ----------
h = doc.add_heading("Rating Legend", level=2)
h.runs[0].font.color.rgb = NAVY
legend_table = doc.add_table(rows=1, cols=3)
legend_table.style = "Table Grid"
hdr = legend_table.rows[0]
labels = [("ESTABLISHED", GREEN, "Consistent with textbook / peer-reviewed sources"),
          ("PARTIALLY SUPPORTED", AMBER, "Real hypothesis in the literature, but contested or not validated for this specific case"),
          ("SPECULATIVE / UNVERIFIED", RED, "Patient-generated extrapolation with no direct literature support")]
for i, (lab, color, desc) in enumerate(labels):
    cell = hdr.cells[i]
    cell.text = ""
    p1 = cell.paragraphs[0]
    run = p1.add_run(lab)
    run.bold = True
    run.font.color.rgb = color
    run.font.size = Pt(9.5)
    p2 = cell.add_paragraph()
    run2 = p2.add_run(desc)
    run2.font.size = Pt(8.5)
    run2.font.color.rgb = GRAY

doc.add_paragraph()

# ---------- Patient Summary ----------
h = doc.add_heading("1. Patient Summary", level=1)
h.runs[0].font.color.rgb = NAVY

summary_items = [
    ("Chief complaint", "Complex auditory hallucinations ('Musical Ear Syndrome') — 16-17 months, evolved from "
     "instrumental music to complex chorus singing in an unknown language."),
    ("Timeline", "Clonazepam cessation Dec 13, 2024 → MES onset ~March 2025 (month 3 post-cessation). "
     "Currently 50+ days into a self-directed magnesium-glycinate-lysinate taper (~78% removed)."),
    ("Comorbidities", "Mal de Débarquement Syndrome (MdDS, recurrent since childhood, re-triggered 2024/2025); "
     "moderate sensorineural hearing loss; hyperacusis."),
    ("Drug sensitivity history", "Carbamazepine (linked by patient to a 2.5-month MdDS episode); lamotrigine "
     "11mg (linked to 2 weeks of MES spikes); magnesium L-threonate (linked to a persistent right-ear tone); "
     "quetiapine declined by patient."),
    ("Requests for this visit", "Neurologist input on a proposed levetiracetam trial, taper safety, lamotrigine "
     "as second-line, continued mirtazapine use, and perampanel as a potential adjunct."),
]
for label, text in summary_items:
    p = doc.add_paragraph(style="List Bullet")
    r1 = p.add_run(f"{label}: ")
    r1.bold = True
    r1.font.size = Pt(10.5)
    r2 = p.add_run(text)
    r2.font.size = Pt(10.5)

doc.add_paragraph()

# ---------- Established ----------
h = doc.add_heading("2. Established Mechanisms (Textbook / Peer-Reviewed Support)", level=1)
h.runs[0].font.color.rgb = NAVY

established = [
    ("Glycine is an obligatory NMDA receptor co-agonist alongside glutamate; without glycine binding, channel "
     "opening does not occur.",
     "Goodman & Gilman's Pharmacological Basis of Therapeutics, p.448; Miller's Anesthesia, 10e"),
    ("Benzodiazepines are positive allosteric modulators of GABA-A receptors; chronic use produces "
     "neuroadaptation (GABA-A downregulation, compensatory glutamatergic upregulation) that is unmasked on "
     "dose reduction/cessation — the accepted mechanism of benzodiazepine withdrawal syndrome.",
     "The Maudsley Deprescribing Guidelines, 'Pathophysiology of Benzodiazepine Withdrawal Syndrome', p.553"),
    ("Chronic benzodiazepine exposure directly increases NMDA receptor activity in preclinical models "
     "(supports a withdrawal-related glutamatergic rebound).",
     "Chapman et al., Neuropharmacology 2025 (PMID 40754183)"),
    ("NR2B-containing NMDA receptors have distinct pharmacological properties (higher glycine affinity, "
     "longer channel open times) versus NR2A-dominant receptors — general receptor pharmacology, not case-specific.",
     "Standard NMDA receptor subunit pharmacology (anesthesia/pharmacology texts)"),
    ("Mirtazapine's receptor profile (5-HT2A antagonism, H1 antagonism) and its effect on slow-wave sleep "
     "restoration are accurately described.",
     "Standard psychopharmacology references"),
    ("Sodium-channel blockers can show inactivated-state/use-dependent selectivity, preferentially affecting "
     "pathologically hyperactive (rapidly firing) circuits over normal circuits — a real pharmacological property.",
     "Standard anticonvulsant pharmacology"),
    ("MdDS core model: maladaptation of the vestibulo-ocular reflex and central 'velocity storage' mechanism "
     "after motion exposure, with symptom relief during re-exposure to movement.",
     "Cummings Otolaryngology–Head & Neck Surgery; K.J. Lee's Essential Otolaryngology; Mucci et al. 2020 "
     "(PMC7683778)"),
    ("Quetiapine/antipsychotics are frequently ineffective for MES because it is a non-psychotic, "
     "non-dopaminergic phenomenon — declining antipsychotic treatment on this basis is a defensible position.",
     "PMC review, 'Frequently Seen But Rarely Diagnosed: Musical Ear Syndrome' (PMC5353248)"),
]

t = doc.add_table(rows=1, cols=2)
t.style = "Table Grid"
header_row(t, ["Claim", "Source / Basis"], [Inches(4.3), Inches(2.5)])
for claim, src in established:
    row = t.add_row()
    add_body_cell(row.cells[0], claim)
    add_body_cell(row.cells[1], src, size=8.5)
    for c in row.cells:
        shade_cell(c, "EAF5EA")

doc.add_paragraph()

# ---------- Partially supported ----------
h = doc.add_heading("3. Partially Supported / Contested Hypotheses", level=1)
h.runs[0].font.color.rgb = NAVY
p = doc.add_paragraph("These are real, actively-studied ideas in the literature, but they are not validated "
                       "specifically for benzodiazepine-withdrawal MES, or remain debated even in their original "
                       "context.")
p.runs[0].font.size = Pt(10)
p.runs[0].italic = True

partial = [
    ("Thalamocortical dysrhythmia (TCD) as the mechanism underlying phantom sound perception (tinnitus) and "
     "chronic neuropathic pain.",
     "Real, ongoing research hypothesis (Kaplan & Sadock's Comprehensive Textbook of Psychiatry; PMID 40945543, "
     "40503593, 39505139, 34608267 — 2024-2025). Not yet an established, validated mechanism specifically for "
     "musical/complex auditory hallucinations in benzodiazepine withdrawal — this is an analogical extension by "
     "the patient, not a documented finding."),
    ("A GABA-deficit contribution to MdDS pathophysiology, layered onto the velocity-storage model.",
     "A GABA/CGRP theory has been proposed (Mucci et al. 2018) but is one hypothesis among several, not the "
     "consensus mechanism."),
    ("Framing MES and MdDS as sharing a single underlying vulnerability (thalamocortical dysrhythmia from "
     "combined GABA deficit + NMDA upregulation) that differs only by circuit.",
     "No literature source directly links these two conditions through a shared TCD/NMDA mechanism — this is "
     "the patient's own synthesis of two separately-studied hypotheses."),
]
t = doc.add_table(rows=1, cols=2)
t.style = "Table Grid"
header_row(t, ["Claim", "Status"], [Inches(3.6), Inches(3.2)])
for claim, src in partial:
    row = t.add_row()
    add_body_cell(row.cells[0], claim)
    add_body_cell(row.cells[1], src, size=8.5)
    for c in row.cells:
        shade_cell(c, "FCF3DA")

doc.add_paragraph()

# ---------- Speculative ----------
h = doc.add_heading("4. Speculative / Unverified Claims", level=1)
h.runs[0].font.color.rgb = NAVY
p = doc.add_paragraph("These claims carry a false sense of precision (specific percentages, ratios, timing "
                       "windows) that is not derivable from symptom history or supplement records, and are not "
                       "found in any textbook or peer-reviewed source reviewed.")
p.runs[0].font.size = Pt(10)
p.runs[0].italic = True

speculative = [
    "Mainstream literature attributes MES primarily to auditory deafferentation/sensory deprivation from "
    "hearing loss, and explicitly states the precise mechanism is unknown (Cleveland Clinic; PMC5353248). The "
    "patient's benzodiazepine-withdrawal/glycine-threshold narrative is a personal causal model layered on top "
    "of — and not equivalent to — the mainstream explanation.",
    "Magnesium glycinate identified as the specific 'threshold-crossing' agent that generated the MES network, "
    "including a stated glycine:magnesium molecular ratio (6.18:1) used to support the causal claim.",
    "Quantified NR2B receptor 'dominance' and receptor density estimates attributed to this patient's own "
    "nervous system.",
    "A specific 15-month timeline for Hebbian consolidation 'migrating' MES maintenance from NMDA-dependent to "
    "AMPA-dominant.",
    "Precise dose-timing pharmacokinetic claims (e.g., glycine peak at 7:15-7:30 PM, dissipation before sleep "
    "onset) presented as an established basis for retiming supplement dosing.",
    "Carbamazepine's HCN-channel activity specifically causing the patient's 2.5-month MdDS episode.",
    "Magnesium L-threonate causing a 'right ear tone' via acute CNS-specific magnesium elevation misinterpreted "
    "by the nervous system as reduced NMDA activity.",
    "Taper-related sensitivity attributed to three named mechanisms (unmasking, reduced Mg2+ channel block, "
    "reduced GABAergic support) presented as a corrected/proven model rather than a working hypothesis.",
    "Levetiracetam and perampanel proposed as targeted treatments for 'AMPA-consolidated' MES — there is no "
    "clinical evidence base for either agent in musical/complex auditory hallucinations; this is an extrapolated "
    "trial proposal from general AMPA/glutamate pharmacology, not a documented indication.",
]
for s in speculative:
    p = doc.add_paragraph(style="List Bullet")
    run = p.add_run(s)
    run.font.size = Pt(10)

doc.add_paragraph()

# ---------- Overall assessment ----------
h = doc.add_heading("5. Overall Evidence Assessment", level=1)
h.runs[0].font.color.rgb = NAVY

p = doc.add_paragraph()
r = p.add_run("Approximate composite: ")
r.bold = True
r.font.size = Pt(11)
r2 = p.add_run("~30-40% of the causal model rests on established, verifiable neuroscience/pharmacology. The "
               "remaining ~60-70% is plausible-sounding but clinically unverified extrapolation, presented with "
               "a level of quantitative precision that exceeds what can be known from symptom history and "
               "supplement records alone.")
r2.font.size = Pt(10.5)

p = doc.add_paragraph()
r = p.add_run("Note: ")
r.bold = True
r.italic = True
r.font.size = Pt(10)
r2 = p.add_run("This percentage is a qualitative synthesis for discussion purposes, not a validated metric. The "
               "individual building-block facts (receptor pharmacology, withdrawal physiology, MdDS "
               "vestibular model) are accurate; it is primarily the disease-specific causal chain connecting "
               "them to this patient's case that is unverified.")
r2.font.size = Pt(9.5)
r2.font.color.rgb = GRAY

doc.add_paragraph()

# ---------- Discussion points ----------
h = doc.add_heading("6. Suggested Discussion Points for This Visit", level=1)
h.runs[0].font.color.rgb = NAVY

discussion = [
    "Ask the neurologist to independently characterize the likely mechanism of MES in this case, rather than "
    "confirming or refuting the patient's pre-built model point-by-point.",
    "Clarify whether thalamocortical dysrhythmia is being invoked as an established diagnosis or as one "
    "plausible framework among several for documentation/prescribing purposes.",
    "Review taper safety and pace independent of the specific 'unmasking vs. upregulation' framing.",
    "Discuss levetiracetam/lamotrigine/perampanel based on their approved indications and general risk profile, "
    "rather than the patient's AMPA/NMDA staging model.",
    "Consider flagging, supportively, the degree of granular self-generated mechanistic detail (exact "
    "percentages, ratios, minute-level timing) as worth exploring in its own right — independent of the "
    "auditory symptoms — given it may be shaping treatment decisions more than the clinical picture warrants.",
]
for d in discussion:
    p = doc.add_paragraph(style="List Number")
    run = p.add_run(d)
    run.font.size = Pt(10.5)

doc.add_paragraph()
footer = doc.add_paragraph()
footer.alignment = WD_ALIGN_PARAGRAPH.CENTER
r = footer.add_run("Prepared as a supporting reference for clinical discussion — not a substitute for independent neurological assessment.")
r.italic = True
r.font.size = Pt(8.5)
r.font.color.rgb = GRAY

doc.save("/tmp/workspace/mes-neurology-summary/output/MES_MdDS_Evidence_Review.docx")
print("Saved.")
Running Command

cd /tmp/workspace/mes-neurology-summary && python3 build_doc.py

Running Command

cd /tmp/workspace/mes-neurology-summary/output && ls -la && python3 -c " from docx import Document d = Document('MES_MdDS_Evidence_Review.docx') print('Paragraphs:', len(d.paragraphs)) print('Tables:', len(d.tables)) for t in d.tables: print('table rows:', len(t.rows), 'cols:', len(t.columns)) "

Document built successfully. It's structured for easy use during the appointment.

MES MdDS Evidence Review

Word Document · DOCX

What's in it:
  1. Purpose statement - frames this as a companion evidence review to the patient's existing "MES Recovery v4" and "MES Clinical Reference — Neurologist" documents
  2. Rating legend - color-coded (green/amber/red) for Established / Partially Supported / Speculative
  3. Patient Summary - chief complaint, timeline, comorbidities, drug sensitivity history, and what's being requested from the neurologist
  4. Established Mechanisms table - 8 claims with textbook/PubMed citations (glycine-NMDA co-agonism, benzodiazepine withdrawal glutamatergic rebound, MdDS velocity-storage model, etc.)
  5. Partially Supported / Contested table - 3 claims (thalamocortical dysrhythmia, GABA-MdDS link, shared MES/MdDS substrate) - flagged as real research hypotheses but not validated for this specific presentation
  6. Speculative / Unverified list - 9 items, including the magnesium-glycinate "threshold-crossing" claim, NR2B quantification, the 15-month AMPA migration timeline, and the levetiracetam/perampanel treatment rationale
  7. Overall Evidence Assessment - the ~30-40% established / ~60-70% speculative composite judgment, with an explicit caveat that this is qualitative, not a validated metric
  8. Suggested Discussion Points - practical prompts for the visit, including one flagging the unusual granularity of the self-generated model as worth discussing independent of the auditory symptoms
The tables are shaded (light green/amber) for quick visual scanning during the visit. Let me know if you want it trimmed down to a one-page version, or want the citation list expanded into a formal reference section.
This is a shared conversation. Sign in to Orris to start your own chat.